PIPERAZINE CALCIUM EDETATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H12N2O8.C4H10N2.Ca.2H
Molecular Weight	416.44
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H+].[H+].[Ca++].C1CNCCN1.[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O

InChI

InChIKey=ROJMAHHOFDIQTI-UHFFFAOYSA-L

InChI=1S/C10H16N2O8.C4H10N2.Ca/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;1-2-6-4-3-5-1;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);5-6H,1-4H2;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula	H
Molecular Weight	1.0079
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H10N2
Molecular Weight	86.1356
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H12N2O8
Molecular Weight	288.2109
Charge	-4
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdf
Curator's Comment: description was created based on several sources, including https://www.alfa.com/en/catalog/043674/

Calcium iodide (chemical formula CaI2) is the ionic compound of calcium and iodine, used in cat food as a source of iodine This colourless deliquescent solid is a salt that is highly soluble in water. Calcium iodide properties are similar to those for related salts, such as calcium chloride. Calcium iodide is also used in photography.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2554
Hypocalcemia 74 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 505	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 171 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 422	Unknown Approved Use Unknown
Cystic fibrosis 119 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 422	Unknown Approved Use Unknown
Unknown 2554
Hypocalcemia 74 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8307	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors.	1999 Feb 26	10026162
Aluminum is a weak agonist for the calcium-sensing receptor.	1999 May	10231437
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein.	1999 Nov	10535458
Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes.	1999 Sep	10469331
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.	1999 Sep	10462554
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.	1999 Sep 20	10509933
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade.	2000 Dec 15	11124974
Inactivation properties of human recombinant class E calcium channels.	2000 Feb	10669483
Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase.	2000 Feb 1	10640419
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation.	2000 Jan 15	10623810
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.	2000 Jan 7	10617657
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways.	2000 Jul 17	10899114
Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A.	2000 May	10843593
Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway.	2000 May	10780946
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.	2000 Nov	11071371
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.	2000 Nov	11040061
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.	2000 Nov 10	11073891
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.	2000 Oct 15	11054866
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension.	2000 Sep	10993766
ATP induces dephosphorylation of myosin light chain in endothelial cells.	2000 Sep	10942722
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake.	2000 Sep	10936204
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.	2001 Apr 27	11278295
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.	2001 Aug	11572466
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line.	2001 Jul	11435619
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.	2001 Jul	11435522
Analysis of the native quaternary structure of vanilloid receptor 1.	2001 Jul 27	11358970
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.	2001 Jun	11356925
Cloning and characterization of a novel human histamine receptor.	2001 Mar	11181941
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.	2001 Mar 15	11238657
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.	2001 Mar 2	11230109
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.	2001 Nov	11701772
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.	2001 Nov 30	11577072
Microarray analysis of differential gene expression in lead-exposed astrocytes.	2001 Oct 1	11578147
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.	2001 Oct 26	11679415
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.	2001 Sep	11500311
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.	2001 Sep 1	11533133
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein.	2001 Sep 15	11535132
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze.	2001 Sep 7	11553362
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.	2002	12421626
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells.	2002 Apr 19	11830588
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.	2002 Dec	12456425
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.	2002 Feb	11872090
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart.	2002 Mar	11856964
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.	2002 Nov 4	12445469
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.	2003 Jan	12388232
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.	2015 Aug 12	26265479

Patents

Sample Use Guides

In Vivo Use Guide

oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:04:42 UTC 2022` Edited by `admin` on `Fri Dec 16 16:04:42 UTC 2022`
Record UNII	L4QEN8344Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIPERAZINE CALCIUM EDETATE

Official Name

English

PIPERAZINE EDETATE CALCIUM [MI]

Common Name

English

PIPERAZINE CALCIUM EDATHAMIL

Common Name

English

PERIN

Brand Name

English

PIPERAZINE EDETATE CALCIUM [USAN]

Common Name

English

piperazine calcium edetate [INN]

Common Name

English

MONOCALCIUM MONOPIPERAZINIUMETHYLENEDIAMINE TETRAACETATE

Common Name

English

CALCIATE(2-), ((N,N'-1,2-ETHANEDIYLBIS(N-(CARBOXYMETHYL)GLYCINATO))(4-)-N,N',O,O',ON,ON')-, (OC-6-21)-, DIHYDROGEN, COMPD. WITH PIPERAZINE (1:1)

Common Name

English

JUSTELMIN

Brand Name

English

PIPERAZINE EDETATE CALCIUM

Official Name

English

Code System Code Type Description

EVMPD

SUB09869MIG